Open AccessGABA B receptor allosteric modulators exhibit pathway‐dependent and species‐selective activity
Author(s) -
Sturchler Emmanuel,
Li Xia,
Lourdes Ladino Maria,
Kaczanowska Kasia,
Cameron Michael,
Griffin Patrick R.,
Finn M. G.,
Markou Athina,
McDonald Patricia
Publication year - 2017
Publication title -
pharmacology research and perspectives
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.975
H-Index - 27
ISSN - 2052-1707
DOI - 10.1002/prp2.288
Subject(s) - allosteric regulation , nicotine , pharmacology , allosteric modulator , in vivo , neuroscience , receptor , chemistry , medicine , biology , biochemistry , microbiology and biotechnology
Positive modulation of the GABA B receptor ( GABA B R ) represents a potentially useful therapeutic approach for the treatment of nicotine addiction. The positive allosteric modulators ( PAM s) of GABA B R GS 39783 and BHF 177 enhance GABA ‐stimulated [ 35 S] GTP γ S‐binding, and have shown efficacy in a rodent nicotine self‐administration procedure reflecting aspects of nicotine dependence. Interestingly, the structural related analog, NVP 998, had no effect on nicotine self‐administration in rats despite demonstrating similar pharmacokinetic properties. Extensive in vitro characterization of GS 39783, BHF 177, and NVP 998 activity on GABA B R ‐regulated signaling events, including modulation of cAMP , intracellular calcium levels, and ERK activation, revealed that these structurally related molecules display distinct pathway‐specific signaling activities that correlate with the dissimilarities observed in rodent models and may be predictive of in vivo efficacy. Furthermore, these GABA B R allosteric modulators exhibit species‐dependent activity. Collectively, these data will be useful in guiding the development of GABA B R allosteric modulators that display optimal in vivo efficacy in a preclinical model of nicotine dependence, and will identify those that have the potential to lead to novel antismoking therapies.